Evidence map›Paper›PMID 41617830›Full record

ArticleEuropean radiology2026

Endovascular revascularisation in chronic occlusive mesenteric ischaemia: safety and efficacy of intravascular lithotripsy.

Annette Thurner, Dominik Peter, Sven Lichthardt, Anne Marie Augustin, Sven Flemming, Ralph Kickuth

Abstract read
In one paragraph

Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Annette ThurnerDepartment of Diagnostic and Interventional Radiology, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany. Thurner_A@ukw.de.ORCID http://orcid.org/0000-0002-5557-6563
Dominik PeterDepartment of General, Visceral, Transplantation, Vascular and Paediatric Surgery, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany.
Sven LichthardtDepartment of General, Visceral, Transplantation, Vascular and Paediatric Surgery, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany.
Anne Marie AugustinDepartment of Radiology, Neuroradiology and Interventional Therapy, Klinikum Bayreuth GmbH, Preuschwitzer Str. 101, 95445, Bayreuth, Germany.
Sven FlemmingDepartment of General, Visceral, Transplantation, Vascular and Paediatric Surgery, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany.
Ralph KickuthDepartment of Diagnostic and Interventional Radiology, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the safety and efficacy of intravascular lithotripsy (IVL)-assisted endovascular revascularisation in patients with chronic mesenteric ischaemia (CMI) and heavily calcified mesenteric artery stenoses. MATERIALS AND

methodsIn this single-centre retrospective study (May 2020-June 2025), consecutive patients with symptomatic CMI, ≥ 50% mesenteric artery stenosis, and moderate-to-severe calcification on CT angiography underwent IVL-assisted endovascular revascularisation. Outcomes included technical success (successful IVL with ≤ 30% residual stenosis after any adjunctive therapy), moderate-to-severe adverse events (AEs), symptom recurrence, clinically driven target vessel revascularisation (CD-TVR), patency, and survival. Kaplan-Meier analysis assessed patency and survival at 6 and 12 months.

resultsFifty-one patients (median age, 71.5 years; 51% women) underwent treatment of 57 arteries (median stenosis, 72.0%; 96.5% moderate-to-severe calcification). IVL was followed by stenting in 53 de-novo lesions (47 bare-metal, 6 covered), and balloon angioplasty in 4 lesions (3 de-novo, 1 in-stent restenosis). Technical success was 93.0%, with predilatation required in 45.6% of vessels. Median residual stenosis was 16.7% (IQR 11.7), and median lumen gain was 3.5 mm (IQR 2.1). Moderate-to-severe AEs occurred in 27.5% of patients. Two patients were lost to follow-up. During a median follow-up of 578.0 days (IQR 529.5), symptom recurrence occurred in 18.4% of patients, and CD-TVR was required in 16.3%. Primary clinical patency was 93.4% at 6 months and 91.0% at 12 months. Survival rates were 91.7% and 89.4% at 6 and 12 months, respectively; mesenteric ischaemia-related mortality was 2.0%.

conclusionIVL is a safe and effective vessel preparation strategy for heavily calcified mesenteric arteries, facilitating endovascular revascularisation in CMI. KEY POINTS: Question Can vessel preparation with intravascular lithotripsy reduce the rate of endovascular treatment failure associated with moderate-to-severe calcification in mesenteric artery stenosis without amplifying procedural risks? Findings Calcium modification with intravascular lithotripsy prior to stenting yielded high technical and clinical success with favourable lumen gain, safety profile, and durable patency. Clinical relevance Adjunctive intravascular lithotripsy is a valuable strategy to mitigate the challenges of calcification in mesenteric artery stenosis, achieving high technical and clinical success while preserving procedural safety, thereby broadening treatment feasibility and improving outcomes in complex disease.

Indexed as

Endovascular ProceduresLithotripsyMesenteric IschemiaMesenteric Vascular OcclusionAgedAged, 80 and overChronic DiseaseComputed Tomography AngiographyFemaleHumansMaleMiddle AgedRetrospective StudiesStentsTreatment OutcomeCalcium modificationChronic occlusive mesenteric ischaemiaIntravascular lithotripsyMesenteric artery stenting

Identifiers

PMID41617830
PMCPMC13212681

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.